

GeoVax has 2-3 Vaccine Candidates in development to respond to the COVID-19 Pandemic. Here is some of the media coverage.

Print:

[A COVID-19 Vaccine, Outsourcing, And Made In The USA](#)



Developing Covid-19 Vaccines at Pandemic Speed - GeoVax listed- Nonreplicating Vector

Vaccine Platforms, Their Attributes, and the Status of Vaccine Candidates.*						
Technology	Attributes				Candidates in Preclinical Development	Candidates in Human Trials
	Single Dose	Licensed Platform	Speed	Current Scale		
DNA	No	No	Fast	Medium	Takis/Applied DNA Sciences/Evvivax Zydus Cadila	Inovio Pharmaceuticals, Phase 1 (NCT04336410)
Inactivated	No	Yes	Medium	Medium to high		Sinovac, Phase 1 (NCT04352608) Inactivated Beijing Institute of Biological Sciences/Wuhan Institute of Biological Sciences, Phase 1 (ChiCTR2000031809)
Live attenuated	Yes	Yes	Slow	High	Codagenix/Serum Institute of India	
Nonreplicating vector	Yes	No	Medium	High	GeoVax/BravoVax Janssen Pharmaceutical Companies Alimmune Greffex Vaxart ExpresS2ion	CanSino Biologics, Phases 1 and 2 (ChiCTR2000030906 and ChiCTR2000031781) University of Oxford, Phase 1/2 (NCT04324606)
Protein subunit	No	Yes	Medium to fast	High	WRAIR/U.S. Army Medical Research Institute of Infectious Diseases Clover Biopharmaceuticals Inc./GSK Vaxil Bio AJ Vaccines Genrex/EpiVax/University of Georgia Sanofi Pasteur Novavax Heat Biologics/University of Miami University of Queensland/GSK/ Baylor College of Medicine iBio/CC-Pharming	
Replicating viral vector	Yes	Yes	Medium	High	Zydus Cadila Institut Pasteur/Themis Tonix Pharma/Southern Research	
RNA	No	No	Fast	Low to medium	Fudan University/Shanghai JiaoTong University/RNACure Biopharma China CDC/Tongji University/Stermina Arcturus/Duke-NUS Imperial College London Curevac BioNTech/Pfizer	Moderna/NIAID (NCT04283461)
Uncertain					University of Pittsburgh University of Saskatchewan ImmunoPrecise MIGAL Galilee Research Institute Doherty Institute Tulane University	

COVID-19 Vaccine Development: An Interview With GeoVax



In the race to treat COVID-19, Georgia companies stake a claim



[GeoVax Progresses in Coronavirus \(COVID-19\) Vaccine Development Program](#)



[Asia Deal Watch: China's BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine - Paywall](#)



The race to stop COVID-19 - GeoVax listed here

IN PERSPECTIVE
IN PERSPECTIVE

THE RACE TO STOP COVID-19

As a new strain of coronavirus threatens public health systems across the globe, researchers are racing to develop a vaccine

BARRY COVVELL & JULIA ROBINSON

In context

Coronavirus is one of a family of viral respiratory diseases, the most well-known coronavirus disease (COVID-19) is currently the most common. It is the global health crisis progression and wider cases are detected. Fluorine (H1N1) 2009 pandemic was estimated to have 15 billion worldwide deaths each year of 100,000 COVID-19 reported by how a million deaths each but potentially 10-4 million.

Symptoms and transmission

- Common symptoms: fever (80%), weakness, cough (70%), fatigue (70%), muscle aches (50%), difficulty breathing (20%).
- Less common symptoms: headache (50%), diarrhea (30%), nausea and vomiting (20%), redness (10%), skin rash (10%).
- Incubation period: 5-14 days.
- Severity: 10-15% of cases die; 80% of cases are mild. 20% are severe and 4-7% are critical. Some have no more than mild symptoms and may not even require hospitalization.
- Transmission: person-to-person spread between close contacts (2 meters) through respiratory droplets.
- Diagnose: COVID-19 is diagnosed based on clinical symptoms and laboratory tests.
- Test: tests to detect virus of COVID-19 are available; specific tests for COVID-19 are not completely available, but clinical tests of some of various steps are being conducted in China.

Care fatality rates for COVID-19

By age:

By gender:

Male	2.8%
Female	1.7%

Global takeover

Vaccine development

There are five main approaches being taken to develop a vaccine against SARS-CoV-2, with various biotechnology companies, academic institutions and pharmaceutical companies employing different strategies in the race to bring their vaccine candidates to clinical trials. The World Health Organization (WHO) hopes that a vaccine will be available by October 2022.

1. Live-attenuated vaccine

- Organizations working on vaccine: Johnson & Johnson, Novartis, AstraZeneca, University of Oxford and AstraZeneca, University of Oxford and AstraZeneca, University of Oxford and AstraZeneca.
- Expected date of first human trials: By August 2020.

2. Inactivated whole virus vaccine

- Organizations working on vaccine: Novartis, AstraZeneca, University of Oxford and AstraZeneca, University of Oxford and AstraZeneca.
- Expected date of first human trials: By August 2020.

3. Subunit vaccine

- Organizations working on vaccine: Novartis, AstraZeneca, University of Oxford and AstraZeneca, University of Oxford and AstraZeneca.
- Expected date of first human trials: By August 2020.

4. mRNA vaccine

- Organizations working on vaccine: Moderna, CureVac, BioNTech, Pfizer, Novartis, AstraZeneca, University of Oxford and AstraZeneca.
- Expected date of first human trials: By August 2020.

5. DNA vaccine

- Organizations working on vaccine: Novartis, AstraZeneca, University of Oxford and AstraZeneca, University of Oxford and AstraZeneca.
- Expected date of first human trials: By August 2020.

Immune response:

- It is not known how long the immune response will last to protect against SARS-CoV-2 infection, some of the vaccine being developed may not work.
- Other candidates may also require booster injections to maintain immunity, but it is not clear how long it will take to develop a SARS-CoV-2 vaccine that is safe and effective.

Landscape of COVID-19 candidate vaccines

